An update on the management of nosocomial pneumonia

Journal of Pharmacy Practice

Volumn 21, Issue 5, 2008, Pages 380-389

  Gupta, Rahul ^a,b   Wargo, Kurt A ^c,d  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUBURN UNIVERSITY   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Antibiotics; Health care associated pneumonia; Nosocomial pneumonia; Treatment; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; ENTEROBACTER; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NONHUMAN; NOSOCOMIAL PNEUMONIA; OTOTOXICITY; PNEUMONIA; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 53549103864     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008318503     Document Type: Review

References (38)

1. Richards MJ, Edwards JR, Culver DH, Gaynes RP Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999 ; 27: 887-892.
2. Fagon JY, Chastre J., Hance AJ, Montravers P., Novara A., Gilbert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993 ; 94: 281-288.
3. Tablan OC, Anderson LJ, Besser R., Bridges C., Hajjeh R. CDC, Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing healthcare-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004 ; 53: 1-36.
4. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 ; 171: 388-416.
5. Chastre J., Fagon JY Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002 ; 165: 867-903.
6. Rello J., Ollendorf DA, Oster G., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002 ; 122: 2115-2121.
7. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998 ; 129: 433-440.
8. Trouillet J-L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998 ; 157: 531-539.
9. El-Solh AA, Sikka P., Ramadan F., Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med. 2001 ; 163: 645-651.
10. Hunter JD Ventilator associated pneumonia. Postgrad Med J. 2006 ; 82: 172-178.
11. Craven DE Preventing ventilator-associated pneumonia in adults: sowing seeds of change. Chest. 2006 ; 130: 251-260.
12. Marquette CH, Herengt F., Mathieu D., Saulnier F., Courcol R., Ramon P. Diagnosis of pneumonia in mechanically ventilated patients. Repeatability of the protected specimen brush. Am Rev Respir Dis. 1993 ; 147: 211-214.
13. Corley DE, Kirtland SH, Winterbauer RH, et al. The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest. 1997 ; 112: 445-457.
14. Torres A., El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. Chest. 2000 ; 117: 198S - 202S.
15. Michaud S., Suzuki S., Harbarth S. Effect of design-related bias in studies of diagnostic tests for ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002 ; 166: 1320-1325.
16. Fagon JY, Chastre J., Wolff M., et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000 ; 132: 621-630.
17. Luna CM, Blanzaco D., Niederman MS, Matarucco W., Baredes NC, Desmery P. Resolution of VAP: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003 ; 31: 676-682.
18. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998 ; 27: 23-27.
19. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 ; 39: 650-655.
20. Paul M., Benuri-Silbiger I., Soares-Weiser K., Leibovici L. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004 ; 328: 668.
21. Gruson D., Hilbert G., Vargas F., et al. Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med. 2000 ; 162: 837-843.
22. Drusano GL, Preston SL, Gotfried MH, Danzinger LH, Rodvold KA Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2002 ; 46: 586-589.
23. Shorr AF, Susla GB, Kollef MH Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Clin Infect Dis. 2005 ; 40: S115 - S122.
24. Wargo KA, Wargo NA, Eiland EH Maximizing pharmacodynamics with high-dose levofloxacin. Hosp Pharm. 2005 ; 40: 777-787.
25. Ray GT, Baxter R., DeLorenze GN Hospital-level rates of fluoroquinolones use and the risk of hospital-acquired infection with ciprofloxacin- nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis. 2005 ; 41: 441-449.
26. Shorr AF, Zadeikis N., Jackson WL, et al. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis. 2005 ; 40: S123 - S129.
27. Tigecycline Evaluation Surveillance Trial. Available at: http://www.testsurveillance.com. Accessed December 6, 2007.
28. Antimicrobial Resistance Management (ARM) program. Available at: http://www.armprogram.com. Accessed December 6, 2007.
29. Trouillet JL, Vuagnat A., Combes A., Kassis N., Chastre J., Gilbert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis. 2002 ; 34: 1047-1054.
30. Moise-Broder PA, Forrest A., Birmingham MC, Schentag JJ Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004 ; 43: 925-942.
31. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996 ; 38: 865-869.
32. Lamer C., De Beco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993 ; 37: 281-286.
33. Jeffres MN, Isakow W., Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus healthcare-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006 ; 130: 947-955.
34. Mohr JF, Murray BE Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007 ; 44: 1536-1542.
35. Conte JE, Golden JA, Kipps J., Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002 ; 46: 1475-1480.
36. Wunderink RG, Rello J., Cammarata SK, Croos-Dabrera RV, Kollef MH Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003 ; 124: 1789-1797.
37. Iregui M., Ward S., Sherman G., Fraser VJ, Kollef MH Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002 ; 122: 262-268.
38. Chastre J., Wolff M., Fagon J-Y., et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA. 2003 ; 290: 2588-2598.